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by Endocannabinoid Signaling
Pathway?
Ewa Jaromin* , Edyta T. Sadowska and Paweł Koteja
Institute of Environmental Sciences, Jagiellonian University, Kraków, Poland
The level of physical activity achieved in a given situation depends on both physiological
abilities and behavioral characteristics (motivation). We used a unique animal model
to test a hypothesis that evolution of an increased aerobic exercise performance can
be facilitated by evolution of motivation to undertake physical activity, mediated by brain
endocannabinoid system. Bank voles (Myodes glareolus) from “aerobic” A lines selected
for 22 generations for high swim-induced aerobic metabolism (VO2swim) achieved
65% higher “voluntary maximum” VO2swim than voles from unselected, “control” C
lines. In C lines, VO2swim was 24% lower than the maximum forced-running aerobic
metabolism (VO2run), while in A lines VO2swim and VO2run were practically the same.
Thus, the selection changed both the aerobic capacity and motivation to exercise at the
top performance level. We applied a pharmacological treatment manipulation to test a
hypothesis that the endocannabinoid signaling pathway 1) affects the voles performance
in the aerobic exercise trials, and 2) has been modified in the selection process.
Administration of the CB1 receptor antagonist (Rimonabant) did not affect the level
of metabolism, but administration of the endocannabinoid reuptake inhibitor (AM404)
decreased VO2swim both in A and C lines (4%, p = 0.03) and tended to decrease
VO2run (2%, p = 0.07). The significant effect of AM404 suggests the involvement
of endocannabinoids in signaling pathways controlling the motivation to be active.
However, the response to AM404 did not differ between A and C lines (interaction
effect, p ≥ 0.29). Thus, the results did not provide a support to the hypothesis that
modifications of endocannabinoid signaling have played a role in the evolution of
increased aerobic exercise performance in our experimental evolution model system.
Summary Statement: The results corroborated involvement of endocannabinoids in
the regulation of physical activity, but did not support the hypothesis that modification of
endocannabinoid signaling played a role in the evolution of increased aerobic exercise
performance in our experimental evolution model.
Keywords: motivation, voluntary exercise, physical activity, endocannabinoids, experimental evolution,
selective breeding
Abbreviations: 2-AG, 2-arachidonoylglycerol; AEA, N-arachidonylethanolamine; eCB, endocannabinoid; VO2, rate of
oxygen consumption; VO2run, the 1-min maximum rate of oxygen consumption achieved during running; VO2swim, the
1-min maximum rate of oxygen consumption achieved during swimming.
Frontiers in Physiology | www.frontiersin.org 1 May 2019 | Volume 10 | Article 640
fphys-10-00640 May 25, 2019 Time: 16:30 # 2
Jaromin et al. Endocannabinoids and Aerobic Performance
INTRODUCTION
The level of physical activity achieved by an animal in a given
situation depends not only on its physiological and biophysical
abilities (e.g., cardiovascular efficiency), but also on motivation to
be active, i.e., neurobiological mechanisms. The neurobiological
basis of the willingness to be active is a subject of intensive
research in both evolutionary biology and medicine. Although
both survival and reproductive success depend on behaviors that
often require increased performance, not all individuals perform
at the upper level of physical abilities (Ekkekakis et al., 2005). As
increased physical activity is simultaneously beneficial and risky,
animals often choose to perform at much slower pace, far from
achieving their physiological limit. Thus, it has been proposed
that the neurobiological rewards could motivate animals to
undertake intensive physical activity and play a significant role
in the evolution of increased physical performance in terrestrial
vertebrates, including humans (Ekkekakis et al., 2005; Raichlen
et al., 2012). The neurobiological mechanism (motivation) can
play a role not only in voluntary physical activity, but also
in procedures designed to measure the maximum forced-
exercise rate of aerobic metabolism (VO2max; Noakes, 2008;
Smirmaul et al., 2013). In applied physiology, the measurement
of VO2max is regarded as a gold standard for evaluation of the
overall physical fitness of both top athletes and patients with
cardiovascular system diseases (Arena et al., 2010). However, it is
controversial if the measured value of VO2max does correspond
to the real aerobic capacity of an organism (Smirmaul et al., 2013).
The details of the neurobiological mechanisms of motivation
to exercise at the top performance level as well as of the
motivation to undertake any physical activity are particularly
important in the context of the prevalence of civilization
diseases associated with low physical activity (Bauman et al.,
2012; Althoff et al., 2017; Rosenfeld, 2017). Here, we tested a
hypothesis that evolution of increased physical performance can
be facilitated by evolution of motivation to be active, mediated
by eCBs signaling.
eCBs are putatively involved in the regulation of physical
activity and in a rewarding feeling after performing strenuous
exercise, a phenomenon known as “the runners high” (Dietrich
and McDaniel, 2004; Raichlen et al., 2012; Heijnen et al.,
2016; Brellenthin et al., 2017; Thompson et al., 2017). An
increased level of eCB, especially AEA and 2-AG, was observed
in rodents and humans following both aerobic and isometric
exercise (Sparing et al., 2003; Heyman et al., 2012; Raichlen
et al., 2012; Koltyn et al., 2014; Brellenthin et al., 2017;
Crombie et al., 2017). AEA and 2-AG are the ligands of
CB1 and CB2 eCB receptors (Kano et al., 2009). CB1 is
highly expressed in brain regions that controls movement,
emotionality and nociception (De Chiara et al., 2010; Dubreucq
et al., 2010, 2013; Gomes da Silva et al., 2010; Raichlen
et al., 2013; Tantimonaco et al., 2014; Fuss et al., 2015).
Interestingly, Raichlen et al. (2012) demonstrated that the
level of AEA in the blood increases after treadmill running
in cursorial animals such as humans and dogs, which often
engage in endurance physical activity, but not in non-cursorial
ferrets. Pharmacological manipulation of eCB system influenced
the level of physical activity in rodent models (review in
Tantimonaco et al., 2014). Thus, it has been suggested that eCB
can motivate high-intensity locomotor behaviors and can be
responsible for a variation in locomotor activity across mammals
(Raichlen et al., 2012).
The studies of neurophysiological or genetic basis of physical
performance are often based on differences between strains of
laboratory rodents (e.g., Avila et al., 2017; Kvedaras et al., 2017)
and the knowledge concerning neurobiological basis of behavior
is severely biased by results from experiments conducted on a
few model species (Keifer and Summers, 2016). Here, we used
a unique experimental evolution model system: lines of a non-
laboratory rodent, the bank vole, from a selection experiment,
comprising four replicate lines of voles selected for 1-min-
maximum aerobic metabolism achieved during swimming test
(VO2swim; A – “aerobic” lines) and four lines of unselected,
randomly bred voles (C – “control” lines). In generation 21,
A-line voles achieved a 58% higher mass-adjusted VO2swim than
C-line voles (Supplementary Figure S1). However, during the
swimming test animals do not necessarily achieve the maximum
aerobic metabolism, as they can “hang” in water with just the
tip of their nose above the water surface. Not surprisingly, in
generation 5, VO2swim was 23% lower than the maximum
aerobic metabolism achieved during forced running on a
treadmill (VO2run; A lines: 21%, C lines: 25%; Supplementary
Materials in Jaromin et al., 2018). Interestingly, in subsequent
generations VO2swim was still lower than VO2run in C lines,
while in A lines the difference decreased and in generations 19–
21 the trait values were practically the same (Jaromin et al., 2016,
2018). Thus, in our model system both the physiological abilities
(the aerobic capacity) and the behavioral trait (willingness to
perform at the upper level of abilities) evolved.
It is well known that changes in neuronal signaling
pathways can lead to an altered response to drugs (Rhodes
et al., 2005; Napolitano et al., 2010). For example, drugs
that stimulate activity in healthy people, can depress it in
patients with dopamine signaling impairment such as Attention
Deficit Hyperactivity Disease (Jafarinia et al., 2012). Thus,
pharmacological manipulations can be effectively applied to
investigate the involvement of particular neurotransmitters
and their receptors in exercise performance of both animals
and humans (review in Roelands and Meeusen, 2010). It
is especially useful when a large group of animals needs
to be measured, as it is in the case of selective breeding
experiments. The approach has been successfully used within
the framework of other selection experiments (e.g., Rhodes
et al., 2001; Rhodes and Garland, 2003; Keeney et al., 2012).
For instance, the activity of mice selected for high wheel-
running behavior decreased after administration of a dopamine
reuptake inhibitor, i.e., a drug that effectively increases the
dopaminergic signaling, but the drug had little effect on
unselected, control mice (Rhodes et al., 2001). This differential
drug response suggested differences in dopamine signaling
between high wheel-runners and control mice. Indeed, the high-
performance liquid chromatography analysis of brain tissue
demonstrated a decreased level of dopamine in high wheel-
runners (Waters et al., 2013).
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We applied the pharmacological approach to investigate
which neuronal signaling pathways underlie the differences
between the A and C-line voles in the willingness to
undertake intensive physical activity. In our previous research,
a decrease in VO2swim was observed after injections of the
reuptake inhibitors of dopamine (8%; vanoxerine), serotonin
(6%; fluoxetine) or norepinephrine (8%; reboxetine), but the
response differed between the A and C-line voles only in
the case of reboxetine (Jaromin et al., 2018). Thus, the
results corroborated the involvement of norepinephrinergic,
serotoninergic and dopaminergic signaling in motivation to
undertake the locomotor activity, but provided an evidence of
a selection-related modification only for the norepinephrinergic
signaling pathway. As the monoaminergic signaling is modulated
by eCB (e.g., Tzavara et al., 2003; review in Kano et al., 2009),
in this study we tested the hypotheses that eCB signaling pathway
(1) affects the voles performance in the aerobic exercise trials, and
(2) has been modified in the selection process. To this end, we
asked (1) if administration of an eCB reuptake inhibitor (AM404)
and a CB1 receptor antagonist (Rimonabant) affect the level of
exercise metabolism, and (2) whether the effect differs between
the A-selected and C-control lines of the voles.
MATERIALS AND METHODS
Animals
This work is based on a typical scheme of artificial selection
studies, in which lines of organisms are selected for many
generations for high or low values of a particular trait, and
then, after the trait is clearly differentiated, correlated responses
in other traits are analyzed, and manipulative experiments are
performed to investigate interactions between the genetically
based effects of selection and environmental effects of the
manipulation (Garland and Rose, 2009).We used bank voles
(Myodes glareolus) from generation 22 of the artificial selection
experiment in which four replicate lines of voles are selected
for the 1-min-maximum rate of oxygen consumption achieved
during 18 min swimming trial at 38◦C (VO2swim; “A” – aerobic
lines) and four replicate lines of unselected, randomly bred voles
(“C” – control lines). Details of the selection experiment and
animal maintenance are described in Sadowska et al. (2008,
2015). In generation 22, we measured VO2swim of 608 voles from
A and 178 voles from C lines at the age of 73–85 days (selection
trial). Voles that were not able to swim for 15 min or were diving
were not chosen for the pharmacological experiment (about 8%
of the A-line and 20% of the C-line voles were excluded for these
reasons). In that way, we chose 6 females and 6 males from each of
the A and C lines (a total of 96) for each of the two experiments
(with AM404 and with Rimonabant). In each experiment each
individual represented a different family.
All procedures associated with the breeding, selection and
experimental procedures were approved by the 1st Local Ethical
Committee on Animal Testing at the Jagiellonian University
in Krakow, Poland (Decision No. 68/2012) and the 2nd Local
Institutional Animal Care and Use Committee (IACUC) in
Krakow, Poland (Decision No. 73/2016).
Pharmacological Experiments
At the age of 78–90 days the voles underwent two measurements
of oxygen consumption during swimming (VO2swim) and
about 2 weeks later two measurements during forced running
(VO2run) after pharmacological manipulation. According to
literature, AM404 and Rimonabant in the doses range of 0.3–
10 mg/kg effectively change physical activity in many different
rodent models (e.g., Adamczyk et al., 2008; Keeney et al., 2008;
Rasmussen and Hillman, 2011; Häring et al., 2013; Llorente-
Berzal et al., 2015; Manna and Umathe, 2015). We chose the
highest dosages of the drugs applied in other studies and
we performed a pilot study to exclude the possibility that
these dosages were too high for bank voles (e.g., causing
immediate sedation, which would preclude swimming trials;
unpublished data). In the proper experiment, with eCB reuptake
inhibitor (AM404), the animals received an injection of AM404
(10 mg/kg) or pure vehicle, in which the drug was dissolved
(DMSO:Tween80:saline 1:0.5:8.5). In the other experiment, with
eCB antagonist (Rimonabant), the animals were injected with
either the Rimonabant (10 mg/kg) or the same vehicle (the level
of VO2swim after the vehicle injection did not differ from that
after saline injection; unpublished results of pilot trials). The
injections were administered in random order and we balanced
the number of each kind of injection administered to voles
from particular line in each trial (i.e., we used a randomized
crossover, counterbalanced design). We maintained at least one
week break between trials to avoid a carry-over effect. All
injections were administered intraperitoneally, in a volume of
10 mL/kg, 30 min before the measurement. AM404 (Tocris,
Abington, United Kingdom) and Rimonabant (Cayman Europe,
Tallinn, Estonia) were diluted in a mixture of DMSO (Tocris,
Abington, United Kingdom), Tween80 (Sigma-Aldrich, Saint-
Louis, United States) and saline ca. 2 h before each trial.
Respirometric Measurements
The respirometric measurements were performed with open-
flow, positive pressure respirometric systems (scheme on
Figure 10.2A in Lighton, 2008), similar to those used in our
earlier experiments on bank voles (Sadowska et al., 2005, 2015;
Jaromin et al., 2018). Fresh air taken from outside of the building
was dried with silica gel and pumped through the respirometric
chamber at about 2,000 ml/min (STPD, measured before the
chamber). The air flow was controlled with mass-flow controllers
(GFC17 or GFC171S, Aalborg, Orangeburg, NY, United States)
and the exact flow values were determined with high precision
glass rotameters (ROTA model L2.5/100). A sample of excurrent
air (about 200 ml/min) was dried with ND2 gas sample drier
(Sable Systems, Las Vegas, NV, United States) and with chemical
absorber (magnesium perchlorate), and directed to FC10 or
FC-10a oxygen and CA-2A carbon dioxide analyzers (Sable
system, Las Vegas, NV, United States). We performed calibration
of the gas analyzers according to FC10, FC10a and CA-2A
manuals. The oxygen analyzers were calibrated at one-point
against clean, dry air, assuming it has a concentration of 20.95%
oxygen. In case of the carbon dioxide analyzer, the adjustment
of zero was performed with respect to carbon dioxide-free and
dry air (carbon dioxide was removed with Ascarite), and the
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adjustment of span with a reference calibration gas containing
0.8% CO2. The analyzers recorded the gas concentrations at 1-s
intervals. The rates of oxygen consumption were calculated with
appropriate respirometric equations (Supplementary Materials
in Sadowska et al., 2015) and corrected for effective volume
to achieve instantaneous rates (Bartholomew et al., 1981;
Lighton, 2008).
To measure the VO2swim we used simultaneously two
systems with respirometric chambers (15 cm diameter 3-liter
glass jars) partly filled with water (38◦C). After recording
the initial baseline for 30 s, the chamber was opened and
the animal was delicately placed on the water surface and
allowed to freely swim. Preliminary observations indicated that
oxygen consumption is higher when the vole swims without any
additional load, presumably because with the additional load they
had difficulty with keeping the head above surface and hence
with breathing. Thus, we did not applied any additional load.
The swimming trial lasted 18 min, except for 7 cases, when the
animals were getting weak (the VO2swim was decreasing) and we
stopped the test. However, these animals achieved their VO2swim
at least 80 s before the test was stopped, and therefore the decision
to stop the trials at a particular moment did not influence the
VO2swim value. After removing the animal from the chamber,
the chamber was closed, and after sufficient washout time (about
2 min) a 30-s final baseline was recorded.
The 1-min-maximum forced-running rate of oxygen
consumption (VO2run) was measured in a respirometric
treadmill for rodents (BTU-100-10-M, Bio-Sys-Tech, Bialystok,
Poland). The animals were forced to run by mild electric shock
(0.5 mA) generated by bars located at the end of the moving
belt. The fur of the abdomen and hind legs was moistened with
warm water (38◦C) that contained a drop of dog shampoo,
to increase electric conductivity. Without that procedure the
animals ignored the mild electric shocks. To decrease velocity
at which the voles achieved the maximum effort (typically 25–
75 m/min), and hence make the procedure safer to the animals,
the treadmill was inclined by 10◦. We also placed two ping-pong
balls at the end of the moving belt, which helped the animals
learn faster to avoid the electric bars. After recording the initial
baseline for 30 s, the vole was placed in the chamber and the
chamber was closed. The treadmill started to move at 5 m/min
one minute after starting the trial and the speed was increased by
5 m/min every minute. The test lasted till exhaustion, i.e., till the
animal was unable to keep pace with the moving belt (typically
5–15 min). The trial was stopped when the vole was pushed
the third time onto the electric bars. As the vast majority of the
voles achieved VO2run well before the trial termination, the
decision of observer about the exact moment of ending the trial
had no practical effect on the results. After removing the vole
from the chamber, the chamber was closed, and after sufficient
washout time (about 2 min) a 30-s final baseline was recorded.
The measurements were preceded by two habituation trials to
familiarize the animals with the treadmill.
Statistical Analysis
We applied nested analysis of covariance (ANCOVA) mixed
models implemented in SAS 9.3 (SAS Institute Inc., Cary, NC,
United States) Mixed procedure (SAS Institute Inc., 2011), with
REML estimation method and variance components constrained
to non-negative values. As several complex models were fitted,
in addition to the description presented here, we provide a
commented SAS code used for the analyses (Supplementary
Tables S1–S3). All the models included main fixed factors of line
Type (selected vs. control), Sex, and line Type × Sex interaction,
and random effects of replicate Line (nested in line Type) and
Sex× Line interaction. The models included also a fixed cofactor
(consecutive Litter Number of a given female, in which the
individual was born: 1, 2 or 3) and two covariates: Age, and
Litter Size. The models in which the VO2swim or VO2run was
the dependent variable included also Body Mass as a covariate.
The models concerning VO2swim included also Respirometric
system number as a cofactor. This basic model structure was
further expanded to accommodate additional factors adequate for
particular datasets:
(1) The models used for analyzing the selection-trial body
mass and VO2swim, measured in all voles from generation
22, included random effect of Family nested in Line. This
effect was introduced to properly handle non-independence
of observations obtained on individuals from the same
full-sib families.
(2) To compare the 1-min maximum rates of oxygen
consumption achieved by the same individuals during
swimming and running (VO2swim vs. VO2run), the basic
model structure was expanded to a repeated-measures
design (with individuals as subjects). The analysis was
performed for results obtained only in trials without
application of the drugs (i.e., only after the vehicle
injections), but pooled from the two pharmacological
experiments. The model included within-subject fixed
factors of Exercise type (swim vs. run; a repeated measure
factor) and Exercise type × line Type interaction, and
random effect of replicate Line× Exercise type. Because the
data pooled from two experiments included observations
on siblings, the model included also between-subject
random effect of Family nested in Line.
(3) Because the pharmacological manipulation was applied at
the within-individual level, a repeated measures model
was also used to analyze data from the pharmacological
experiments. First, we tested the additive effect of the drugs
on 1-min-maximum swim-induced VO2 (VO2swim), the
time of achieving VO2swim, whole swimming trial mean
VO2 (mean VO2swim), and 1-min-maximum run-induced
VO2 (VO2run), separately for the two experiments (with
AM404 or Rimonabant). These models included the
following within-subject (within-individual) effects: fixed
factor of Drug (depending on the experiment: AM404 vs.
vehicle or Rimonabant vs. vehicle), Drug × line Type
interaction, trial Number as the repeated measure factor,
and random replicate Line × Drug effect. The effect of
Family was not included in these models, because each
vole used within one experiment (AM404 or Rimonabant)
represented a different family. Based on Akaike information
criteria (AIC) we chose models with equal residual
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variances for the replicated trials as better than those with
unequal variances.
(4) Next, we used the repeated measures models to test the
multiplicative effect of the drugs. Here the dependent
variable was the ratio of a VO2 achieved after drug to
that after vehicle (proportional response). The analysis was
performed for the VO2swim and VO2run ratios in one
model, but separately for the two experiments (with AM404
or Rimonabant). These models included within-subject
fixed factors of the Exercise type (swim vs. run, a repeated
measure factor) and Exercise type × line Type interaction,
and random effect of replicate Line× Exercise type.
All initial models included also interactions between Sex and
main factors. However, these effects were not of main interest
and were excluded from the final models when not significant
(p > 0.05). To test for the homogeneity of slopes, initial models
for VO2swim and VO2run included also interactions between
Body Mass and the main factors, which were excluded from the
final models when not significant. The slope for selection-trial
VO2swim was significantly steeper in A than in C lines and the
heterogeneous slopes had to be retained in the final model. In
the analyses of data from the pharmacological experiments the
differences of slopes were not statistically significant. However,
these analyses were based on a dataset smaller than that available
for selection trial, and, consequently, the power to detect the
slope heterogeneity was lower. Moreover, in our earlier work we
observed significant differences between the slopes in A and C
lines (Jaromin et al., 2016, 2018; Rudolf et al., 2017). Therefore, we
decided to retain the heterogeneous slopes also in the ANCOVAs
performed on data from pharmacological experiments. Retention
of the heterogeneous slopes in the models precluded a general
test of difference between the level of VO2 in A and C lines.
Therefore, to check whether the levels of VO2 differ between the
line Types in the range of observed body mass, we tested this
effect at specific values of the body mass covariate (option “at” in
LSMEANS statement in the SAS Mixed procedure; SAS Institute
Inc., 2011). For a more transparent presentation of the results, the
adjusted Least-Squares Means (LSM) presented on Figures were
calculated at mean values of covariates (body mass, age and Litter
size: 24 g, 78 days and 6 in selection trial, and 24 g, 85 days and
5.5 in further trials).
We checked distribution of residuals by inspecting SAS-
generated diagnostic graphs (plots of residual vs. predicted
values, histograms, and quantile plots). We excluded statistical
outliers from the analysis when the studentized residual was
higher than 3.0. In that way we excluded one outlier from the
analysis of proportional response to AM404 and two outliers
from the analysis of proportional response to Rimonabant. In
the analysis of selection-trial VO2swim for all voles in generation
22, i.e., a much larger sample, we increased the threshold to
3.5 (two outliers were excluded). The exclusion of the outliers
improved the distribution of residuals, but did not influence final
conclusions. The residuals distribution in the analysis of the time
of achieving VO2swim was somewhat heteroscedastic. Square-
transformation improved the residuals distribution, but results
of the analysis were similar and lead to the same conclusions.
Therefore, for the clarity of presentation, we report here the
raw data analysis. In all models, we used the Satterthwaite’s
approximation to calculate the effective denominator degrees of
freedom (dfs) of the F statistics or df in t statistics (SAS Institute
Inc., 2011). Shortly, in the model with nested random effects,
the appropriate denominator dfs are computed as combination
of the dfs of appropriate random effects (e.g., the nested factor
effects and residual term) weighted by variance contributed
by the effects. When the variance of the nested factor (in
our case replicate Lines nested in line Type) approaches zero,
the appropriate denominator df approach the dfs for residual
error term (which reflects the fact that in the absence of the
among-group variance, individual observations can be effectively
treated as statistically independent). Thus, when the Satterthwaite
method is used, the denominator dfs can take any real value from
the range between the df of the nested random factor and the df
of residual term (but for clarity of presentation, the Satterthwaite
dfs were rounded to whole numbers).
Unless otherwise stated, we used Tukey-Kramer for multiple
pairwise comparisons between groups. We tested the significance
of random factors with likelihood ratio test (LRT), using models
such as described above, but with the variance constrain relaxed
(“nobound” option in SAS Mixed procedure).
In the Results section, we report main effects of line Type
and Drug. Comprehensive statistical results are presented in
Supplementary Materials: descriptive statistics (Supplementary
Table S4), detailed information about all others fixed factor
effects (Supplementary Tables S4–S9), and estimation of
variance components and LRT tests (Supplementary Table S10).
RESULTS
In the selection trial, body mass ranged from 14.6 to 36.9 g and
mean body mass (24 g) did not differ significantly between A and
C lines (F1,6 = 1.93, p = 0.21, Figure 1A and Supplementary
Table S4). Males were heavier than females (F1,7 = 102,
p < 0.0001) and the line Type × Sex interaction was not
significant (F1,7 = 1.09, p = 0.33). The 1 min-maximum swim-
induced (VO2swim) oxygen consumption increased with Body
Mass and the slope of the relationship between VO2swim and
Body Mass was steeper in A-lines (slope difference ± SE:
0.05 ± 0.015, t191 = 3.58, p = 0.0004; Figure 1A and
Supplementary Table S5). At the minimum body mass in the
dataset (14.6 g), voles from A lines achieved a higher VO2swim
than voles from C lines (t86 = 11.5, p < 0.0001) and, as the
difference increased with body mass, we can conclude that
the difference in VO2 between voles from A and C lines was
significant for the whole range of body mass (at mean body
mass = 24 g, t8 = 18.9, p < 0.0001). The mean values of
VO2swim in two subsets of A- and C-line voles sampled for the
pharmacological experiments were almost exactly the same as the
respective means for all the animals used in the selection trial
(Supplementary Table S4).
In the analysis concerning the exercise type effect (combined
data from both pharmacological experiments), body mass
ranged from 14.7 to 35.5 g and mean body mass (24 g) did
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FIGURE 1 | The relationship between swim-induced (VO2swim) or run-induced (VO2run) 1-min maximum rate of oxygen consumption and body mass in bank voles,
and the effects of selection, sex, and pharmacological manipulation. (A) VO2swim in all individuals from generation 22 (C – Control lines, A – Aerobic lines) tested as
a part of the selection experiment (selection-trial results). (B) The effect of Exercise Type (VO2swim vs. VO2run) in voles from C (N = 96) and A (N = 96) lines (voles
used in AM404 and Rimonabant experiments combined). (C,D) The effect of AM404 [an endocannabinoid (eCB) reuptake inhibitor] on VO2swim (C) and VO2run (D):
repeated trials in a subsample of voles from C (N = 48) and A (N = 48) lines. (E,F) The effect of Rimonabant (a cannabinoid receptor CB1 antagonist) on VO2swim
(E) and VO2run (F): repeated trials in a subsample of voles from C (N = 48) and A (N = 48) lines. Dotted lines indicate the mean body mass for which the adjusted
least-squares means were calculated (shown in Figures 2–4 and Supplementary Table S4).
not differ between A and C lines (F1,6 = 5.55, p = 0.06,
Figure 1B and Supplementary Table S4). Males were heavier
than females (F1,6 = 116, p < 0.0001) and the line Type × Sex
interaction was not significant (F1,6 = 0.0, p = 0.97). Both the
1-min-maximum swim-induced (VO2swim) and run-induced
(VO2run) oxygen consumption increased with Body Mass
(Figure 1B and Supplementary Table S5). Although the line
Type× Body Mass interaction was not significant in this analysis,
we decided to retain it in the final models (see Methods). Overall
ANCOVA for mean body mass (24 g) revealed that both the
selection, the exercise type, and their interaction affected the
rate of metabolism (Type: t6 = 8.65, p = 0.0001; Exercise Type:
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F1,7 = 67.1, p < 0.0001, line Type × Exercise Type: F1,7 = 26.9,
p = 0.0011; Figures 1B, 2, 3A,D, 4A,D and Table 1). Voles
from A lines achieved a generally higher VO2 than voles from C
lines (partitioned analysis; VO2swim: F1,8 = 102.2, p < 0.0001;
VO2run: F1,8 = 35.6, p = 0.0003). Voles from the A lines had
also a higher “mean VO2swim,” i.e., the average VO2 in the
entire swimming trial (usually about 15 mins; Figures 3C, 4C and
Table 1). The analyses performed for the minimal and maximal
body mass showed the same pattern for the differences between
A and C lines in all the aerobic performance traits, thus we
could conclude that the same conclusions concern the whole
range of body mass. In A lines VO2run was only 3% higher than
VO2swim and the difference was not significant (F1,7 = 4.48,
p = 0.07), while in C lines VO2run was 32% higher than VO2swim
(F1,7 = 89.8, p< 0.0001).
The administration of eCBs reuptake inhibitor (AM404),
resulted in decreased VO2swim (4%, F1,6 = 7.71, p = 0.03),
mean VO2swim (5%, F1,6 = 15.4, p = 0.007) and tended to
decrease VO2run (2%, F1,79 = 3.39, p = 0.07), but the line
Type × Drug interaction had no significant effect on any of
the three traits (p ≥ 0.29; Figures 1C,D, 3A,C,D, Table 1 and
Supplementary Table S4). The time of achieving VO2swim did
not differ significantly between A and C lines (t88 = 1.45, p = 0.15)
and was not affected by the Drug (F1,94 = 2.61, p = 0.11) or line
Type × Drug interaction (F1,94 = 0.04, p = 0.84; Figure 3B and
Table 1). Note that in the additive models (results reported above)
the line Type × Drug interactions conveys the information
on the hypothetical effect of selection on eCB pathways. On
the other hand, in the analysis of the proportional response to
the drug (the ratio of VO2 achieved after drug to that after
vehicle) the hypothetical effect of selection on eCB pathways
is expressed directly in the line Type effect. The proportional
response, however, was not influenced significantly by the line
Type (t12 = 0.45, p = 0.66, Figure 3E and Table 2), Exercise type
FIGURE 2 | The maximum rate of oxygen consumption achieved during
selection trial and pharmacological trials: swim trials 1 and 2, and run trials 1
and 2 (only the trials after placebo-vehicle injections), in bank voles from
selected A lines (n = 96) and unselected C lines (n = 96). The adjusted least
squares means for the mean body mass (24 g) with 95% confidence limits are
presented [LSM(95%CL) note: an overlap of the confidence limits does not
indicate a lack of difference between repeated measurements at different
conditions, because the confidence limits are based on among-individual
variation at particular conditions, whereas the inferences concerning
differences between conditions are based on within-individual comparisons.
See Table 1 for results of the proper significance tests].
(F1,13 = 2.71, p = 0.12) or line Type × Exercise type interaction
(F1,13 = 0.02, p = 0.88).
The administration of eCB receptor antagonist (Rimonabant)
had no effect on VO2swim, mean VO2swim or VO2run, and
the line Type × Drug interaction was not significant, either
(p ≥ 0.70; Figures 1E,F, 4A,C,D, Table 1 and Supplementary
Table S4). The time of achieving VO2swim did not differ between
the A and C lines (t6 = 0.69, p = 0.52) or Drug (F1,92 = 0.4,
p = 0.52), but the line Type × Drug interaction was significant
(F1,92 = 4.64, p = 0.03; Figure 4B and Table 1). This is because
injection of the drug tended to decrease the time of achieving
VO2swim in C lines, but increase it in A lines. However, in the
analyses performed for A and C lines separately, the drug effect
was not significant (in A lines: F1,46 = 1.80, p = 0.19, C lines:
F1,45 = 2.86, p = 0.10). In the analysis of proportional response
(VO2 achieved after drug to that after vehicle) the effects of line
Type (t6 = 0.34, p = 0.75), Exercise type (F1,5 = 0.15, p = 0.72),
line Type× Exercise type (F1,6 = 2.10, p = 0.20) or Sex× Exercise
type interaction (F1,80 = 3.39, p = 0.07) were not significant
(Figure 4E and Table 2). However, Line Type × Sex × Exercise
type interaction was significant (F1,81 = 7.15, p = 0.009). That was
because the proportional response was higher in females than in
males from C lines during swimming, but during running the
opposite was observed (the response was lower in females than
in males; Tukey comparisons: swim C-lines: females vs. males:
t123 = 3.28, p = 0.03, Supplementary Table S9).
DISCUSSION
As expected, in generation 22 bank voles from the A-selected
lines achieved 65% higher mass-adjusted swim-induced aerobic
metabolism (VO2swim) than voles from C-control lines
(Figures 1, 2). Similarly as in the previous generations (Jaromin
et al., 2016, 2018), in C lines the VO2swim was 24% lower than
the maximum forced-running aerobic metabolism (VO2run),
but in the A lines the levels of VO2swim and VO2run were
nearly the same (Figures 1B, 2). Thus, the voles from A lines
evolved both the increased aerobic capacity and willingness to
voluntarily undertake physical activity at the level approaching
their physiological limit. To investigate the neuronal mechanism
underlying the differences in motivation to be active between
voles from A and C lines we measured VO2swim and VO2run
after injections of drugs modulating eCB signaling.
Application of the CB1 receptor antagonist (Rimonabant) had
no significant effect on VO2swim or VO2run (Figures 4A,D),
but it caused a differential effect on the time of achieving
VO2swim (Figure 4B). Specifically, voles from C lines achieved
VO2swim faster, while those from A lines later after Rimonabant
injection when compared to vehicle (significant line Type×Drug
interaction). However, the drug effects in the analyses performed
for A and C lines separately were not significant. Interestingly,
the proportional response to Rimonabant during swimming
(VO2swim after Rimonabant to that after vehicle) was higher
in females than males from C lines and during running it was
the opposite (Figure 4E). The sex differences in the response
to eCB-modulating drugs were reported in literature, e.g., eCB
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FIGURE 3 | Summary of the main results from experiment with AM404 – an endocannabinoid reuptake inhibitor: repeated trials in a subsample of voles from
selected A (n = 48) and unselected C lines (n = 48). (A) 1-min maximum swim-induced oxygen consumption (VO2swim). (B) The time when voles achieved the
VO2swim. (C) Whole-trial mean VO2swim (typically about 15 min). (D) 1-min maximum run-induced oxygen consumption (VO2run). (E) The ratio of VO2swim or
VO2run achieved after drug to the one after vehicle (proportional response). Bars represent adjusted least squares mean with 95% confidence limits (LSM[95%CL]
Note: as explained in Figure 2 legend, an overlap of the confidence limits does not indicate that a difference is not significant. See Figure 5 and Tables 1, 2 for
results of the proper significance tests).
agonist (tetrahydrocannabinol) increased locomotor activity in
females, but had no effect in males (Wiley, 2003). In another
selection experiment, Rimonabant decreased running to a greater
degree in female mice selected for high voluntary wheel running
than in selected males or control, unselected mice (Keeney
et al., 2008). Current literature provides strong evidence of sex
differences in physical activity level in humans and rodents that
can be of genetic, hormonal or neuronal basis, however the
exact mechanism remains unclear (review in Rosenfeld, 2017). To
summarize, the effects of Rimonabant on the traits measured in
bank voles are weak, and the results are not conclusive. However,
the marginally significant interactions indicate that further
investigation of the effects of other eCB antagonists is worthwhile.
On the other hand, administration of the eCB reuptake
inhibitor (AM404) significantly decreased the 1-min-
maximum VO2swim (4%; Figure 3A), mean VO2swim
(5%; Figure 3C), and it tended to decrease VO2run in all
voles (2%; Figure 3D). The literature provides confusing
results concerning the influence of eCB-modulating drugs
on the voluntary physical activity. Although direct brain
microinjections of eCB agonist increased locomotor activity
in rats and established conditioned place preference (Zangen
et al., 2006), the systemic administration of eCB agonists
either increased or decreased locomotor activity (review in
Tantimonaco et al., 2014). According to Almeida et al. (2014),
open-field locomotor activity increased in wild-type rats and
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FIGURE 4 | Summary of the main results from experiment with Rimonabant – cannabinoid receptor CB1 antagonist: repeated trials in a subsample of voles from
selected A (n = 48) and unselected C lines (n = 48). (A) 1-min maximum swim-induced oxygen consumption (VO2swim). (B) The time when voles achieved the
VO2swim. (C) Whole-trial mean VO2swim (typically about 15 min). (D) 1-min maximum run-induced oxygen consumption (VO2run). (E) The ratio of VO2swim or
VO2run achieved after drug to the one after vehicle (proportional response). Bars represent adjusted least squares mean with 95% confidence limits [LSM(95%CL)
Note: as explained in Figure 2 legend, an overlap of the confidence limits does not indicate that a difference is not significant. See Figure 5 and Tables 1, 2 for
results of the proper significance tests].
TABLE 1 | Main results of mixed ANCOVA models (effects of selection, pharmacological treatment and their interaction) for the data obtained in the two experiments with
pharmacological manipulation (AM404 – an endocannabinoid reuptake inhibitor or Rimonabant – cannabinoid receptor CB1 antagonist).
Experiment Line type Drug Line type × Drug
Trait t (df) P-value F (Ndf, Ddf) P-value F (Ndf, Ddf) P-value
AM404 experiment
VO2swim 15.6 (8) <0.0001 7.82 (1,6) 0.03 1.00 (1,6) 0.35
time at VO2swim 1.45 (88) 0.15 2.61 (1,94) 0.11 0.04 (1,94) 0.84
mean VO2swim 13.6 (8) <0.0001 15.4 (1,6) 0.007 1.32 (1,6) 0.29
VO2run 5.90 (7) 0.0005 3.39 (1,79) 0.07 0.47 (1,79) 0.49
Rimonabant experiment
VO2swim 14.2 (21) <0.0001 0.02 (1,8) 0.90 0.12 (1,8) 0.73
time at VO2swim 0.69 (6) 0.52 0.43 (1,92) 0.52 4.64 (1,92) 0.03
mean VO2swim 12.6 (9) <0.0001 0.08 (1,7) 0.78 0.02 (1,7) 0.91
VO2run 5.76 (7) 0.0006 0.01 (1,6) 0.94 0.15 (1,6) 0.71
VO2swim, VO2run – 1-min maximum swim-or run-induced rate of oxygen consumption; mean VO2swim, whole-trial mean VO2swim; F or t statistics; df, degrees of
freedom; Ndf, numerator df; Ddf, denominator df; see Supplementary Tables S7, S8 for results concerning additional factors in the ANCOVA models.
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TABLE 2 | Proportional response – the ratio of VO2 achieved after drug to the one after vehicle in voles used in the two experiments with pharmacological manipulation
(AM404 – an endocannabinoid reuptake inhibitor or Rimonabant – cannabinoid receptor CB1 antagonist).
Experiment Line type Exercise type Line type × Exercise type
t (df) P-value F (Ndf, Ddf) P-value F (Ndf, Ddf) P-value
AM404 experiment 0.45 (12) 0.66 2.71 (1,13) 0.12 0.02 (1,13) 0.88
Rimonabant experiment∗ 0.34 (6) 0.75 0.15 (1,5) 0.72 2.10 (1,6) 0.20
Main results of mixed ANCOVA models (effects of selection, exercise type and their interaction) are presented; F or t statistics; df, degrees of freedom; Ndf, numerator
df; Ddf, denominator df; see Supplementary Table S7, S8 for results concerning additional factors in the ANCOVA model. ∗Sex × Exercise type: F1,80 = 3.39, p = 0.07;
Line type × Sex × Exercise type interaction: F1,81 = 7.15, p = 0.009.
FIGURE 5 | The effects of Rimonabant (cannabinoid receptor CB1 antagonist) and AM404 (endocannabinoid reuptake inhibitor on the measured traits): (A–D) Mean
within-individual differences between the values obtained after drug treatment and vehicle injection [(A) 1-min maximum swim-induced oxygen consumption
(VO2swim); (B) the time when voles achieved the VO2swim; (C) whole-trial mean VO2swim; (D)1-min maximum run-induced oxygen consumption (VO2run)]. Bars
represent the least squares estimates of the mean differences with 95% confidence limits.
decreased in hyperactive rats after systemic injection of AM404.
However, in other studies AM404 decreased the open-field
locomotor activity also in wild-type rats (Beltramo et al.,
2000) or had no significant effect (Adamczyk et al., 2008).
Moreover, both the agonist and antagonist of CB1 receptor
decreased voluntary wheel running in mice (Keeney et al., 2008,
2012). It seems that the results of different tests designed to
measure voluntary activity (e.g., open filed, wheel running,
home-cage activity) may not be correlated (Careau et al., 2012).
The contradictory findings can result not only from different
conditions of the experiment, but also from the complexity
of the eCB system and the eCB-exercise interplay, which are
still not fully recognized (Tantimonaco et al., 2014). As the
response to drugs differs greatly between species and even
strains (e.g., Petit-Demouliere et al., 2005), the decrease in
voluntary physical activity after AM404 administration can be
specific for bank voles.
The forced-running protocols are widely applied to measure
the maximum capacity for physical activity, however it is also
known that they do not warrant that the result is free from
the behavioral responses, such as willingness to undertake the
exercise (Smirmaul et al., 2013). What is more, the mild electric
shocks, applied as stimulator in the VO2run tests, can cause an
eCBs release (Guindon and Hohmann, 2009). Administration of
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AM404 decreased VO2run in the voles, but the effect was two
times smaller than in case of VO2swim. It could be hypothesized
that the application of AM404 affected not the motivation
to undertake activity, but a regulatory or metabolic pathway
determining the aerobic exercise capacity of the voles (even
though, to our knowledge, such effects have not been reported).
However, if this were the case, the application of AM404
would lead to a larger change of the forced-exercise VO2run
than of the voluntary-exercise VO2swim. As the opposite was
observed, we conclude that AM404 affected a mechanism
regulating a behavioral aspect of the locomotor activity rather
than the ability to perform work. Thus, the results are consistent
with the hypothesis of involvement of the eCB signaling in
mechanisms regulating motivation to undertake the activity.
However, we cannot exclude a possibility that the AM404
affected some other behavioral aspect of activity, such as arousal,
rather than motivation per se. Thus, the conclusion requires
further support.
To investigate the effect of selection on eCB signaling
pathway we tested line Type × Drug interactions in additive
models and line Type effect in the proportional response
analysis. Despite the complexity of eCB signaling, a distinct
reaction to drugs administration in the A and C lines would
indicate that eCB signaling pathway has been changed in
the course of selection. However, although AM404 resulted
in decreased aerobic metabolic rates both in the swimming
and running trials, we did not find any differences in
the response to AM404 between voles from A and C
lines. This negative result does not exclude the possibility
that eCB signaling has changed under the influence of
selection, but with such a simple scheme of pharmacological
manipulation some subtle modifications in the eCB signaling
could remain undetected.
To summarize, the results provided further evidence for the
involvement of eCB in the regulation of physical activity and
especially in the willingness to undertake intensive exercise.
However, the results did not support the hypothesis that an
alternation of eCB signaling pathway have played a role in
the evolution of increased aerobic exercise performance in our
experimental evolution model. Because the pharmacological
approach has several limitations (e.g., not complete specificity
of the drugs and their systemic application), the conclusions
require an additional support. As the selection experiment
is continued, further studies can answer the question which
neurobiological mechanism underlies the evolutionary changes
in motivation to be active.
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